Journal article
Serial circulating tumour DNA analysis during multimodality treatment of locally advanced rectal cancer: A prospective biomarker study
J Tie, JD Cohen, Y Wang, L Li, M Christie, K Simons, H Elsaleh, S Kosmider, R Wong, D Yip, M Lee, B Tran, D Rangiah, M Burge, D Goldstein, M Singh, I Skinner, I Faragher, M Croxford, C Bampton Show all
Gut | BMJ PUBLISHING GROUP | Published : 2019
Abstract
Objective For patients with locally advanced rectal cancer (LARC), adjuvant chemotherapy selection following surgery remains a major clinical dilemma. Here, we investigated the ability of circulating tumour DNA (ctDNA) to improve risk stratification in patients with LARC. Design We enrolled patients with LARC (T3/T4 and/or N+) planned for neoadjuvant chemoradiotherapy. Plasma samples were collected pretreatment, postchemoradiotherapy and 4-10 weeks after surgery. Somatic mutations in individual patient's tumour were identified via massively parallel sequencing of 15 genes commonly mutated in colorectal cancer. We then designed personalised assays to quantify ctDNA in plasma samples. Patients..
View full abstractGrants
Awarded by National Institute of General Medical Sciences
Funding Acknowledgements
Australian National Health and Medical Research Council (GNT1026230), the National Institute of Health (CA62924, GM07309, and P30-CA006973), Virginia and D K Ludwig Fund for Cancer Research, The John Templeton Foundation, The Conrad R Hilton Foundation, The Sol Goldman Sequencing Facility at Johns Hopkins.